Prostate cancer remains a leading cause of cancer-related death in men, largely attributable to distant metastases, most frequently to bones. Despite intensive investigations, molecular mechanisms underlying metastasis are not completely understood. Among prostate cancerderived factors, parathyroid hormone-related peptide (PTHrP), first discovered as an etiologic factor for malignancy-induced hypercalcemia, regulates many cellular functions critical to tumor growth, angiogenesis, and metastasis. In this study, the role of PTHrP in tumor cell survival from detachment-induced apoptosis (i.e. anoikis) was investigated. Reduction of PTHLH (encoding PTHrP) gene expression in human prostate cancer cells (PC-3) increased the percentage of apoptotic cells when cultured in suspension. Conversely, overexpression of PTHrP protected prostate cancer cells (Ace-1 and LNCaP, both typically expressing low or undetectable basal PTHrP) from anoikis. Overexpression of nuclear localization signal (NLS)-defective PTHrP failed to protect cells from anoikis, suggesting that PTHrP-dependent protection from anoikis is an intracrine event. A PCR-based apoptosis-related gene array showed that detachment increased expression of the TNF gene (encoding the proapoptotic protein tumor necrosis factor-a) fourfold greater in PTHrP-knockdown PC-3 cells than in control PC-3 cells. In parallel, TNF gene expression was significantly reduced in PTHrP-overexpressing LNCaP cells, but not in NLSdefective PTHrP overexpressing LNCaP cells, when compared with control LNCaP cells. Subsequently, in a prostate cancer skeletal metastasis mouse model, PTHrP-knockdown PC-3 cells resulted in significantly fewer metastatic lesions compared to control PC-3 cells, suggesting that PTHrP mediated antianoikis events in the bloodstream. In conclusion, nuclear localization of PTHrP confers prostate cancer cell resistance to anoikis, potentially contributing to prostate cancer metastasis.
Introduction
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancerrelated death in males worldwide, notwithstanding the improved early detection methods and therapeutic modalities (Jemal et al. 2011) . Advanced-stage prostate cancer patients commonly develop metastatic lesions, most frequently in the skeleton, which ultimately account for the high mortality rate as well as severe morbidities (Weilbaecher et al. 2011) . In sharp contrast, the molecular mechanism leading to metastasis is not yet completely understood. Metastatic colonization in distant organs requires disseminating tumor cells to have essential cellular functions, such as invasion of extracellular matrices, survival in the bloodstream, extravasation, and adaptation to the new environment (Langley & Fidler 2011) , which are mediated by numerous tumor-derived factors. Prostate cancer is uniquely positioned because of its strong propensity to interact with and metastasize to bone. In this regard, prostate cancer cells express numerous bone-modulating cytokines including parathyroid hormone-related peptide (PTHrP), osteoprotegerin, receptor activator of nuclear factor-kB ligand, and others (Deftos et al. 2005) . However, contributions of these bone-modulating factors to metastasis remain under investigation.
PTHrP was first discovered as an etiologic factor for malignancy-induced hypercalcemia by increasing osteoclastogenesis . Later, PTHrP expression was identified in carcinoma cells, such as lung, breast, and prostate cancer cells , Iwamura et al. 1993 , Downey et al. 1997 . Similar to its physiologic counterpart, PTH, PTHrP binds to its cognate PTH/PTHrP receptor (PPR) expressed on osteoblasts and also found in some tumor cells (Downey et al. 1997 , Iddon et al. 2000 , triggering the cyclic AMP/protein kinase A signal transduction pathway. In addition to autocrine/paracrine effects mediated by receptor binding, PTHrP has been shown to localize to the nucleus, leading to the inhibition of apoptosis in chondrocytes and prostate cancer cells (Henderson et al. 1995 , Dougherty et al. 1999 . Chondrocytes expressing PTHrP with a deletion of the nuclear localization signal (NLS) showed increased apoptosis (Henderson et al. 1995) , indicating that PTHrP functions as an antiapoptotic factor. However, the potential role of PTHrP in tumor cells, particularly in the context of metastatic cascades, is under investigation. For example, tumor cells are triggered to undergo apoptosis when the cells lose attachment to their extracellular matrix, a cellular phenomenon termed anoikis. Evasion of anoikis in the metastatic process (e.g. in the bloodstream) is essential for successful colonization of tumor cells in distant organs .
In this study, the function of PTHrP in the context of prostate cancer was examined using an in vitro anoikis model as well as an in vivo experimental bone metastasis model. PTHrP protected prostate cancer cells from anoikis, effects of which were mediated by nuclear localization of PTHrP and reduced expression of tumor necrosis factor-a (TNF-a). Prostate tumor cells expressing lower PTHrP resulted in significantly fewer metastatic lesions compared to cells expressing higher PTHrP, potentially mediated by increased anoikis due to loss of intracrine PTHrP activity.
Materials and methods

Cells
PC-3, LNCaP, and Ace-1 prostate carcinoma cells were selected to study the function of PTHrP, because PC-3 cells express high levels of endogenous PTHrP while LNCaP and Ace-1 cells do not express detectable PTHrP. The canine prostate carcinoma cell line (Ace-1) was kindly provided by Dr Thomas Rosol (Ohio State University, USA; LeRoy et al. 2006 , Thudi et al. 2011 . Cells were maintained as monolayer cultures in RPMI-1640 media supplemented with 10% v/v fetal bovine serum and 1! penicillin/streptomycin and glutamate (all from Invitrogen). For in vivo bioluminescence imaging, luciferase-labeled PC-3 cells (designated PC-3 Luc ) were produced by stably transfecting a luciferase-expressing pLazarus retroviral construct as previously described (Schneider et al. 2005) . In addition, PTHLH (NCBI reference number: NM_198966) gene expression was reduced in PC-3 Luc cells via a lentiviral vector (pLenti4/Block-iT DEST vector; Invitrogen) expressing short hairpin RNA targeting 5 0 -GGGCAGATACCTAACTCAGGA-3 0 .
An empty vector was used as a control. Lentiviral supernatants were prepared using 293T packaging cells (the University of Michigan Viral Vector Core Laboratory, Ann Arbor, MI, USA), followed by transduction of PC-3 Luc cells with polybrene (6 mg/ml). Subsequently, transduced cells were grown in bleomycin selection media (Zeocin 200 mg/ml; Invitrogen), and stable clones were selected and expanded for further experiments.
LNCaP and Ace-1 cells normally express undetectable basal levels of PTHrP. Both cell lines were stably transfected with full-length PTHrP, NLS-defective PTHrP (i.e. amino acids 87-107) (Henderson et al. 1995) , or empty pcDNA3.1 vectors, as previously described (Dougherty et al. 1999 , Liao et al. 2008 .
Measurement of PTHrP
PTHrP expression was measured from the culture supernatant using an IRMA kit (Diagnostic Systems Laboratories, Webster, TX, USA), detecting amino acids 1-87 (Ratcliffe et al. 1991) . Briefly, one million cells were seeded in a six-well plate in complete RPMI-1640 media (in triplicate), followed by media change with serum-free RPMI-1640 24 h later. Subsequently, cells were incubated for 48 h and cellfree supernatants collected. The PTHrP assay was performed as suggested by the manufacturer. 
Calculation of in vitro doubling time
PTHrP-knockdown and empty vector control PC-3 Luc cells were synchronized (by overnight serum starvation), followed by seeding (1!10 5 cells/well, in triplicate) and enumeration at 24, 48, 72, and 96 h later with the aid of a hemacytometer and trypan blue dye. The doubling time (T d ) was calculated using the formula: T d Z(T 2 KT 1 )!(log2/log(Q 2 /Q 1 )), where Q 1 and Q 2 are cell numbers at two time points (T 1 and T 2 ) respectively.
In vivo tumor growth
All animal experimental protocols were approved and performed in accordance with current regulations and standards of the University of Michigan's Institutional Animal Care and Use Committee guidelines.
For in vivo tumor growth, male athymic mice (Hsd: Athymic nude -Foxn1 nu ; 4 weeks old; Harlan Laboratories, Indianapolis, IN, USA) were anesthetized and 100 ml of cell suspension containing 1!10 6 cells were mixed with 100 ml of growth factor reduced Matrigel (Invitrogen), and injected subcutaneously into both flanks (nZ10 each group). After 3 weeks, bioluminescence imaging was performed to measure tumor size, followed by euthanasia and tumor tissue harvesting.
Anoikis assay and flow cytometry
To induce anoikis in vitro, prostate cancer cells were cultured in suspension as previously described (Minard et al. 2006) . Briefly, six-well tissue culture plates were covered with 4% w/v endotoxin-free agarose. Prostate cancer cells were w80% confluent at the initiation of overnight serum-starvation (for synchronization). Subsequently, cells were trypsinized and counted, followed by seeding of 1!10 6 cells/well in RMPI-1640 media supplemented with 2% v/v fetal bovine serum on regular culture plates or agarose-covered plates (in sextuplicate). After 12-16 h of incubation at 37 8C, cells were harvested by pipetting (for cells in suspension) or trypsinization (for attached cells), followed by washing with ice-cold PBS and centrifugation.
For flow cytometric analyses, cells were re-suspended in Annexin V binding buffer (BD Biosciences, San Jose, CA, USA), followed by addition of FITCconjugated anti-Annexin V and propidium iodide (BD Biosciences). Subsequently, cells were washed once with ice-cold PBS and analyzed by flow cytometer (BD FACSCalibur) with CellQuest analyses software (BD Biosciences). (Li et al. 2011) . Analyses of data were performed using computer software provided by the manufacturer. A complete list of 84 apoptosis-related genes included in the analyses, detailed protocols, and analysis method can be found at the manufacturer's website (http://www.sabiosciences.com/rt_pcr_product/HTML/ PAHS-012A.html).
In vivo metastasis model
To test the metastatic potentials of PC-3 Luc clones, cells were inoculated into the systemic circulation via intracardiac route, as previously described (Park et al. 2011a) , followed by in vivo bioluminescence imaging. In brief, male athymic mice (Hsd: Athymic nude -Foxn1 nu ; 6 weeks old; Harlan Laboratories) were anesthetized and 100 ml of cell suspension containing 2!10 5 cells were injected into the left heart ventricle. Systemic circulation of the tumor cells was confirmed by in vivo bioluminescence imaging immediately after inoculation. Metastatic hind limb tumors were detected and quantified by bioluminescence imaging (Caliper Life Sciences, Alameda, CA, USA). Tumor-bearing hind limb bones were harvested at euthanasia, fixed in 10% v/v buffered formaldehyde and decalcified in 10% w/v EDTA for 2 weeks. Metastatic tumor cells were microscopically confirmed.
Cytokines and antibodies
Recombinant human TNF-a and anti-human TNF-a neutralizing antibodies were purchased from Peprotech, Inc. (Rocky Hill, NJ, USA). For western blotting, anti-PTHrP antibody (H-137: a rabbit polyclonal antibody against amino acids 41-177 of human PTHrP) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Statistical analyses
All statistical tests were performed by Microsoft Excel or GraphPad Prism Version 5 (La Jolla, CA, USA). Student's t-test was used to compare two groups and the P!0.05 level was considered statistically significant. All statistical tests were two-sided and data expressed as a meanGS.D.
Results
PTHrP-knockdown reduced in vivo tumor growth without affecting in vitro proliferation As a first approach to investigate the function of PTHrP in prostate cancer cells, PTHLH gene expression was reduced in PC-3
Luc human prostate cancer cells using an shRNA technique. Stable clones were confirmed and selected according to level of PTHrP expression (Fig. 1A) in the cell culture supernatants. Two knockdown clones (clone no. 5 and 10) showed more than 50% reduction of PTHrP expression compared to parental PC-3
Luc cells, while an empty vector control clone also showed mild reduction, but not to the extent of clones 5 and 10. PTHrP has been shown to regulate cellular proliferation (Dougherty et al. 1999 ). However, cell enumeration assays demonstrated that PTHrP-knockdown did not affect in vitro cellular doubling time of PC-3
Luc cells (Fig. 1B ), suggesting that the reduced level of PTHrP expression was sufficient to maintain cellular proliferation, at least in PC-3 Luc cells which express high basal levels of PTHrP. In contrast, PTHrP-knockdown resulted in significantly reduced tumor growth in vivo (Fig. 1C) , suggesting that PTHrP regulates tumor cell proliferation and/or survival via a mechanism other than direct regulation of cell proliferation.
Reduction of PTHrP expression sensitized PC-3 Luc cells to detachment-induced apoptosis
In routine maintenance subculturing, differential plating efficiency among PTHrP-knockdown and control clones was noted, leading to a hypothesis that PTHrP-knockdown PC-3 cells are more prone to detachment-induced apoptosis. To test this, PC-3
Luc cells and PTHrP-knockdown clones were grown in suspension for an extended time, followed by flow cytometric analyses of apoptotic cells. Detachment increased the percentage of apoptotic Annexin V C PI K PC-3 Luc cells ( Fig. 2A and B) , and empty vector control cells (Fig. 2C) . Interestingly, PTHrP-knockdown clones had a significantly increased percentage of Annexin V C PI K apoptotic cells (Fig. 2D , E and F), PTHrP overexpression rescued Ace-1 prostate cancer cells from anoikis
To further investigate the role of PTHrP in anoikis, an alternative approach (i.e. ectopic expression of PTHrP) was employed. An additional prostate cancer cell line, Ace-1, had been previously shown to express undetectable levels of PTHrP (Liao et al. 2008) . A PTHrP overexpression vector or empty pcDNA3.1 vector (as a control) was transfected into Ace-1 cells, resulting in Ace-1 PTHrP clone 10 and Ace-1 pcDNA respectively. PTHrP expression was measured and confirmed by IRMA of culture supernatants. The Ace-1 PTHrP clone 10 expressed 282.2G9.83 (pg/ml per 1!10 6 cells per 48 h), while Ace-1 pcDNA control cells expressed undetectable levels of PTHrP. Cells were induced to undergo anoikis by culturing in suspension (Fig. 3) . PTHrP overexpressing Ace-1 cells had significantly fewer apoptotic cells compared to Ace-1 pcDNA control cells (Fig. 3A, B Luc cell culture which contains full-length PTHrP was added to PTHrP-knockdown PC-3 clones in suspension. Neither recombinant PTHrP (1-34) nor the conditioned media rescued PTHrP-knockdown PC-3 cells from anoikis (Fig. 4) , suggesting that PTHrPdependent survival is not via N-terminus paracrine effects.
Overexpression of full-length PTHrP, but not NLS-defective PTHrP, rescues prostate cancer cells from anoikis PTHrP localizes to the nucleus and has been shown to protect colon tumor cells from drug-induced apoptosis (Shen et al. 2007a , Bhatia et al. 2009b ). This mechanism was evaluated on PTHrP-or NLS-defective PTHrP overexpressing prostate tumor cells. Human prostate cancer cells, LNCaP, expressing undetectable basal levels of PTHrP were engineered to express full-length PTHrP (designated PTHrP OE), NLS-defective PTHrP (designated PTHrP DNLS), or pcDNA3.1 (as a control) (Fig. 5G ). Cells were cultured in suspension to induce anoikis, followed by flow cytometric analyses. Interestingly, NLS-defective PTHrP failed to rescue LNCaP (Fig. 5A , B, C, D, E and F). Overall, Figs 1, 2, 3 , 4 and 5 demonstrate that PTHrP promotes prostate tumor cell survival from detachment-induced apoptosis via an intracrine manner (nuclear localization) and not a paracrine manner, potentially contributing to tumor growth in vivo.
Detachment induced greater TNF-a expression in PTHrP-knockdown PC-3 cells than in empty vector control cells
To investigate downstream mediators of PTHrPdependent anoikis, a quantitative PCR-based gene array (detecting 84 human apoptosis-related genes) experiment was performed. Detachment-induced genes were identified by comparing mRNA from cells cultured in an agarose-covered plate with cells cultured on a regular plate (columns (A) and (B) in Table 1 ). Among 84 apoptosis-related genes tested, tumor necrosis factor-a (TNF) gene expression was increased more than fourfold in PTHrP-knockdown PC-3 cells compared to empty vector control PC-3 cells, indicating an inverse correlation of PTHrP nuclear localization with a proapoptotic gene (TNF).
NLS-defective PTHrP failed to decrease TNF in response to detachment
To validate the observation in the gene array data (Table 1) , detachment-induced TNF expression was confirmed in an additional cell line (LNCaP) expressing full-length PTHrP or NLS-defective PTHrP. Overexpression of PTHrP in LNCaP cells significantly reduced TNF gene expression, while NLS-defective PTHrP failed to do so, supporting a negative correlation between PTHLH expression and TNF (Fig. 6A) . Data from Figs 1, 2, 3, 4, 5, 6 and Table 1 all together demonstrated that prostate tumor cells expressing higher PTHrP have increased resistance to anoikis by suppressing a proapoptotic gene (TNF).
Recombinant TNF-a promotes anoikis and neutralizing TNF-a protects cells from anoikis
The causal role of TNF-a in PTHrP-dependent anoikis was further examined. Recombinant human TNF-a administration promoted anoikis in empty vector control PC-3 cells (Fig. 6B ). More importantly, neutralizing TNF-a reduced the percentage of apoptotic PTHrP-knockdown PC-3 cells in an in vitro anoikis experiment model (Fig. 6C) . These results establish the 
Reduction of PTHrP expression decreased prostate cancer skeletal metastasis
The biological significance of PTHrP-dependent resistance to anoikis was examined using an experimental prostate cancer skeletal metastasis model. Prostate cancer cells expressing high PTHrP were anticipated to produce more metastatic lesions via increased survival in the bloodstream, compared to prostate cancer cells expressing low PTHrP (Fig. 7) . In our previous experiments, PC-3 cells develop metastatic lesions predominantly in bones (i.e. hind limbs and mandibles) in an intracardiac injection model (Schneider et al. 2005 , Park et al. 2011a . Accordingly, PTHrP-knockdown or empty vector PC-3
Luc cells were introduced into the systemic circulation and skeletal lesions were measured via in vivo bioluminescence imaging 5 weeks later. Because of differential in vivo growth rates (Fig. 1C) , instead of comparing hind limb tumor size (quantified by photon emission from each lesion), incidence of hind limb metastatic lesions was reasoned to be a more appropriate comparison.
PTHrP-knockdown PC-3
Luc (clone no. 10) produced significantly fewer hind limb metastatic lesions compared to empty vector control PC-3
Luc cells, potentially due to decreased survival from anoikis in the bloodstream.
Discussion
The current study demonstrated that tumor-derived PTHrP promotes prostate cancer metastasis, in part, by conferring resistance to anoikis, and that the PTHrPdependent protection from anoikis is mediated by nuclear translocalization. Reduction of PTHLH gene expression in PC-3 luc human prostate cancer cells did not alter in vitro cellular proliferation but significantly decreased in vivo tumor growth, suggesting that PTHrP regulates cellular functions (evasion of apoptosis) in addition to previously known effects on proliferation. Indeed, PTHrP-knockdown cells had impaired ability to attach to the culture plates, leading to investigation of the mechanisms of PTHrP protection from anoikis. However, the discrepancy between in vitro proliferation and in vivo tumor growth might be attributable to other cellular functions. First, as wild-type PC-3 cells express high basal levels of PTHrP, reduction of PTHrP-expression to 20-40% (in PTHrP-knockdown clones 5 and 10) may not be sufficient to affect cellular proliferation, but enough to sensitize the cells to apoptotic stimuli. In addition, as PTHrP has been shown to regulate tumor angiogenesis (Liao et al. 2008) , effects on in vivo tumor growth could simply be secondary to reduced angiogenesis. Murine endothelial cell-specific CD31/PECAM immunohistochemistry of the tumor tissue confirmed that PTHrP-knockdown tumors had significantly reduced mean vessel density (data not shown). Lastly, because PTHrP functions as a mediator in the crosstalk between the primary tumor and the bone/bone marrow, where a conducive environment is present, prostate tumors expressing low PTHrP may grow slower because of reduced recruitment of bone marrow-derived cells with tumorigenic functions (Park et al. 2011b) . On the other hand, subsequent data (Figs 2, 3, 4 and 5) clearly demonstrated that PTHrP nuclear translocalization protects prostate tumor cells from anoikis, partly contributing to suppression of in vivo tumor growth of PTHrP-knockdown cells.
Antiapoptotic effects of PTHrP were first demonstrated in chondrocytes (Henderson et al. 1995) , mediated by upregulation of the antiapoptotic protein BCL-2 (Amling et al. 1997) . Later, PTHrP was shown to protect LoVo colon tumor cells from apoptosis by upregulating the PI3K/AKT pathway (Shen et al. (Bhatia et al. 2009a) , of which observations were expanded by our current study. Therefore, PTHrP-mediated protection from apoptosis can be generalized to multiple inducers of apoptosis (e.g. chemotherapy, detachment, etc.) , which can account for the correlation between PTHrP expression and metastatic potential of tumor cells (Hiraki et al. 2002 , Liao & McCauley 2006 . Apoptosis induced by disrupted epithelial cell-matrix interactions was described by Frisch & Francis (1994) , and termed 'anoikis.' Evasion of anoikis was reasoned, and later proved to be a critical function of metastatic tumor cells (Yawata et al. 1998 . Data from the present study expand the role of PTHrP in protecting prostate tumor cells from anoikis, leading to decreased skeletal metastasis in PTHrP-knockdown cells compared to control PC-3 cells.
Interestingly, the PCR-based gene array data demonstrated that PTHrP prevents anoikis by downregulating the proapoptotic gene TNF, which was confirmed in an additional human prostate cancer cell line. However, the mechanism of transcriptional downregulation by nuclear translocalization of PTHrP is unclear and requires further investigation. One potential mechanism underlying PTHrP-regulated gene expression is interaction with RNA. Aarts et al. (1999) demonstrated that nuclear PTHrP interacts with mRNA, which may lead to degradation of transcripts. Recently, deletion of mid-region, nuclear localization, and C-terminus of PTHrP (i.e. protein domains other than N-terminus which are recognized by the cognate receptor) decreased expression of genes essential for skeletal development (Runx1, Runx2 and Sox9) while increasing expression of cell cycle inhibitors (p21 and p16), supporting a role for PTHrP in transcriptional regulation (Toribio et al. 2010) . Therefore, despite lack of definitive experimental evidence, nuclear localization of PTHrP may play critical roles in regulating gene expression, resulting in cellular phenotypes such as protection from apoptosis.
The current study has potential clinical significance by providing an additional molecular mechanism contributing to prostate cancer skeletal metastasis. Reduction of PTHrP resulted in decreased metastatic In conclusion, the current study demonstrates a role for PTHrP in protecting prostate tumor cells from anoikis in vitro, downregulating TNF gene expression, and supporting metastatic potential of prostate tumor cells in vivo.
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